Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Hemangiosarcoma 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Esophagogastric Cancer 1Colonic Neoplasms 1Adenocarcinoma of the Prostate 1

Interventions

Ipilimumab 10pembrolizumab 7Nivolumab 7incomplete Freund's adjuvant 6Temozolomide 5Dacarbazine 5tebentafusp 4Sunitinib 4MART-1 Antigen 4Carboplatin 4CTLA-4 Antigen 4sargramostim 3montanide ISA 51 3aflibercept 3Paclitaxel 3Bevacizumab 3trametinib 2relatlimab 2olaparib 2lenvatinib 2cediranib 2Vorinostat 2Thalidomide 2Taxes 2Sorafenib 2Radiosurgery 2MAGEA3 protein, human 2Lenalidomide 2Interleukin-2 2Interleukin-12 Subunit p35 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uveal Melanoma × STA 9090 × Clear all
NCT01200238 2018-10-18

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Dana-Farber Cancer Institute

Phase 2 Completed
17 enrolled 12 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡